Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CAR-T
Biotech
Cellectis will shed 70% of workforce as part of in vivo pivot
Cellectis’ pivot from allogeneic CAR-Ts to in vivo therapies is set to come at the expense of 70% of its workforce.
James Waldron
Nov 13, 2026 9:18am
Generate sees ‘huge opportunity’ using Claude to improve CAR-Ts
Nov 6, 2026 10:02am
BMS sheds light on patient death in CAR-T trial
Oct 26, 2026 7:00am
Roche CEO has ‘absolutely not’ changed view on Poseida buyout
Oct 22, 2026 4:16am
Rebranded Galapagos finally finds buyer for cell therapies
Oct 15, 2026 4:09am
Caribou’s ‘heartbreaking’ call to lay off staff, halt pipeline
Oct 7, 2026 5:00am